Shahrin Ahmed: The results of a melanoma jab trial were extremely impressive
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared on X:
“The results of a melanoma jab trial were extremely impressive –
According to the world’s first personalized mRNA cancer vaccine for melanoma, the risk of patients dying or the disease reoccurring is reduced, as shown in the trial results that described as ‘extremely impressive’.
World Cancer Research Fund International’s 2020 figures indicate that melanoma affects more than 150,000 people globally every year. After receiving the vaccine for stage 3 or 4 melanoma, patients had a 49% lower risk of death or disease recurrence after three years.
The largest cancer conference featured data that demonstrated. One of the organizations that is testing the vaccine is the NHS in the UK. The vaccine-Keytruda combination had a survival rate of 74.8% for 2.5 years, while Keytruda alone had a survival rate of 55.6%.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago was attended by delegates who heard. The results demonstrate the significant potential of therapeutic cancer vaccines when combined with powerful immunotherapies.
The jab, known as mRNA-4157 (V940), is custom-made for each patient and instructs their body to destroy any remaining cancer cells and prevent the disease from returning.
400 patients with early stage breast cancer were studied. A vaccine was administered to half of them to boost their immune systems prior to surgery.
81% of patients who received the vaccine are still alive and cancer-free after seven years, while only 65% of patients who received standard care are still alive and cancer-free.”
Source: Shahrin Ahmed/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023